Filtered Listing Testing

Alzheimer’s Disease Research, a BrightFocus program, is partnering with IQVIA™️, a healthcare research firm that is looking for people to take part in a medical research study to help learn more about an investigational medication (or a “study drug”) for dementia-related apathy.

A team of BrightFocus-funded scientists has proposed a new explanation and possible new target for treatment in glaucoma that’s unrelated to the common culprit of eye pressure.

David Liao, MD, offers insights into managing and understanding AMD and what forthcoming FDA approval could mean for treatment.

Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.

If approved, the drug pegcetacoplan would become the first-ever treatment in the U.S. for geographic atrophy, a blinding and advanced form of age-related macular degeneration.

More than 75 graduate students, postdoctoral fellows, and other early-career scientists from around the world participated in this year’s BrightFocus Alzheimer’s Fast Track, Nov. 9-11, 2022, in San Diego.